Liver Diseases  >>  sofosbuvir/velpatasvir  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sofosbuvir/velpatasvir / Generic mfg.
ASTRAL-1, NCT02201940 / 2014-001683-35: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Checkmark DDW 2016 (ASTRAL-1)
Apr 2016 - Apr 2016: DDW 2016 (ASTRAL-1)
Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
741
Canada, US, Europe, RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816, Placebo
Gilead Sciences
Hepatitis C Virus Infection
06/15
09/15
ASTRAL-4, NCT02201901: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
268
US
SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV
Gilead Sciences
Hepatitis C Virus Infection
08/15
11/15
ASTRAL-3, NCT02201953 / 2014-001682-27: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
558
Canada, US, Europe, RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816, SOF, Sovaldi®, GS-7977, PSI-7977, RBV
Gilead Sciences
Hepatitis C Virus Infection
09/15
12/15
GS-US-342-1446, NCT02346721 / 2014-003898-42: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Completed
3
111
Canada, US, Europe, RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
03/16
06/16

Download Options